HALEOS LABS LIMITED (HALEOSLABS) Share Price
NSE · Healthcare · Biotechnology · ISIN INE320X01016
Key metrics
- Market Cap
- ₹448 Cr
- P/E Ratio
- 28.36
- EPS
- 52.24
- Book Value
- 759.29
- P/B Ratio
- 1.95
- ROE
- 7.54%
- ROCE
- 8.59%
- Debt / Equity
- 0.48
- Net Margin
- 5.19%
- Revenue Growth
- -3.17%
- Profit Growth
- -13.91%
- Dividend Yield
- 0.1%
- 52W High
- ₹1,774.00
- 52W Low
- ₹1,091.10
- Market Cap Band
- micro cap
- Face Value
- 10
Ratios computed from the annual results period ending 2026-03-31.
About HALEOS LABS LIMITED
Haleos Labs Limited engages in the manufacturing of active pharmaceutical ingredients (API) and intermediates in India. The company offers API and intermediates in areas, such as anti-ulcer, anti-migraine, anti-hypertensive, erectile dysfunction, anti-cancer, antifungal, anti-obesity, anti-emetic, anti-depressant, anti-worm, anti-infective, anti-gout, anti-convulsant, antiviral, and anesthesia, as well as antihistamine, diuretics, hair loss, and ophthalmic API products. It also exports its products. The company was formerly known as SMS Lifesciences India Limited and changed its name to Haleos Labs Limited in August 2025. Haleos Labs Limited was founded in 1990 and is based in Hyderabad, India.
- Headquarters
- Hyderabad, India
- Promoter Holding
- 74.97%
The full HALEOS LABS LIMITED analysis
Create a free account to open the complete HALEOSLABS deep-dive — fourteen tabs of fundamental, technical, institutional and ownership data.
- 10-year financialsIncome statement, balance sheet and cash flow, year by year.
- Valuation & fair valueFair-value estimates, quality scores and a value grade.
- Charts & technicalsCandlestick charts, RSI, MACD, Supertrend and detected patterns.
- Shareholding historyPromoter, FII, DII and public holdings across every quarter.
- Ace investor holdingsWhich well-known investors hold it, and how their stake changed.
- Deals & insider tradesBulk and block deals, insider transactions and mutual-fund holdings.